Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
28 hedge funds and large institutions have $25M invested in Eagle Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 12 closing their positions.
2% more capital invested
Capital invested by funds: $24.4M → $25M (+$561K)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$2.48M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$354K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$164K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$140K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.27M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1M |
| 3 |
Jennison Associates
New York
|
-$897K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$364K |
| 5 |
State Street
Boston,
Massachusetts
|
-$271K |
EGRX Hedge Fund Activity: Q2 2014 in Review
28 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2014, worth a combined $25M — up 2.3% from $24.4M a quarter earlier.
Fund positioning in EGRX was balanced in Q2 2014: 12 funds opened new positions, 12 closed out, 5 added to existing stakes and 6 trimmed.
The largest buyer was Park West Asset Management, adding an estimated $2.48M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.27M sold.
- 28 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $25M of Eagle Pharmaceuticals, Inc. stock for Q2 2014, up 2.3% quarter-over-quarter.
- 12 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2014 and 12 closed out, a net change of 0 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2014 was Park West Asset Management, an estimated $2.48M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2014 was JP Morgan Chase, an estimated $2.27M sold.
Based on aggregated 13F filings for Q2 2014.